Search results for "R&D portfolio"

showing 5 items of 5 documents

A real options based support system to open innovation

2012

Pharmaceutical R&D process (PR&DP) has been deeply investigated by different streams of literature; the interest is due to the strategic implication of the related decisions undertaken. The PR&DP has been revolutionised by the biotech advent and as a consequence R&D managers cannot avoid to consider Open Innovation paradigm during this decision process. Starting from a Real Option optimization model available in literature, the paper aims at proposing a decision support system (DSS) able to suggest the candidate products to be included in the best R&D portfolio varying input parameters (resilient products), to provide a products Pareto analysis that aims at individuating the products for wh…

R&D portfolioSettore ING-IND/35 - Ingegneria Economico-GestionaleOpen Innovation Biopharmaceutical industryReal OptionsDSS
researchProduct

Real Options Analysis (ROA)opens innovation: the biopharmaceutical case

2012

Open Innovation Real Options Analysis R&D Portfolio Biopharmacuetical industry
researchProduct

A real options based model to select a balanced R&D portfolio

2011

The R&D process in the pharmaceutical industry has a long and dynamic life then it is an ideal field of application for ROA. Actually, ROA implementation, as widely demonstrated in literature, is narrowed to very limited cases because its perceived complexity. This research wants to suggest a simplified method, respect the ones available in literature, that could foster the use of ROA: we built up an integer linear programming model, based on a model available in literature, useful for selecting a balanced R&D portfolio from a set of candidate drugs. The model has been tested through a case study.

R&D portfolioPharmaceutical IndustryReal Options AnalysiSettore ING-IND/35 - Ingegneria Economico-Gestionale
researchProduct

Open innovation: A real option to restore value to the biopharmaceutical R&D

2014

The pharmaceutical landscape has changed, and new business models, based on alliances, are increasingly being adopted in this industry. Biotechnology advances have pushed this development, and pooling complementary resources coming from incumbents and newcomers is a key skill to succeed: these are the premises for a quick spread of the open innovation (OI) paradigm in this industry. R&D portfolio selection needs R&D project evaluation, and Real Options Analysis (ROA) is acknowledged as a powerful tool to evaluate uncertain projects that have an intrinsic flexibility. The present research aims to foster the use of ROA in the OI field in order to encourage firms to undertake this innovation mode…

R&D portfolioOpen innovationLicensingReal options analysiSettore ING-IND/35 - Ingegneria Economico-GestionaleBiopharmaceutical industry
researchProduct

An affordable way to implement real options to select optimal R&D portfolio

2011

Real option Analysis (ROA) is acknowledged as a powerful tool to evaluate uncertain projects whose uncertainty depends heavily on alternatives available along the project life. The R&D process in the pharmaceutical industry has a long and dynamic life then it is an ideal field of application for ROA. Actually, ROA implementation, as widely demonstrated in literature, is narrowed to very limited cases because its perceived complexity. This research wants to suggest a simplified method, respect the ones available in literature, that could foster the use of ROA: we built up an integer linear programming model, based on a model available in literature, useful for selecting the optimal R&D produ…

R&D portfolioPharmaceutical IndustryReal Options AnalysiSettore ING-IND/35 - Ingegneria Economico-Gestionale
researchProduct